Adjuvant CCNU (Lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors

Journal of the American Animal Hospital Association

Volumn 45, Issue 1, 2009, Pages 14-18

  Hosoya, Kenji ^a   Kisseberth, William C ^a   Alvarez, Francisco J ^a   Lara Garcia, Ana ^a   Beamer, Gillian ^a   Stromberg, Paul C ^a   Couto, C Guillermo ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

ALKYLATING AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LOMUSTINE; PREDNISONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG COMBINATION; FEMALE; LIVER FAILURE; MALE; RETROSPECTIVE STUDY; SARCOMA; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; LIVER FAILURE; LOMUSTINE; MALE; MAST-CELL SARCOMA; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 62849128339     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0450014     Document Type: Article

References (28)

1. Macy DW. Canine and feline mast cell tumors: biologic behavior, diagnosis, and therapy. Semin Vet Med Surg (Small Anim) 1986;1: 72-83.
2. al-Sarraf R, Mauldin GN, Patnaik AK, Meleo KA. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. J Vet Intern Med 1996;10:376-378.
3. Frimberger AE, Moore AS, LaRue SM, Gliatto JM, Bengtson AE. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). J Am Anim Hosp Assoc 1997;33:320-324.
4. LaDue T, Price GS, Dodge R, Page RL, Thrall DE. Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound 1998;39:57-62.
5. Turrel JM, Kitchell BE, Miller LM, Theon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 1988;193:936-940.
6. Poirier VJ, Adams WM, Forrest LJ, Green EM, Dubielzig RR, Vail DM. Radiation therapy for incompletely excised grade II canine mast cell tumors. J Am Anim Hosp Assoc 2006;42:430-434.
7. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
8. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994;8:406-408.
9. McCaw DL, Miller MA, Bergman PJ, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997;11:375-378.
10. Gerritsen RJ, Teske E, Kraus JS, Rutteman GR. Multi-agent chemotherapy for mast cell tumours in the dog. Vet Q 1998;20:28-31.
11. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
12. Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 2007;68:1246-1251.
13. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1-7.
14. Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124-130.
15. Northrup NC, Harmon BG, Gieger TL, et al. Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 2005;17:245-248.
16. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
17. VCOG-CTCAE. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
18. Thamm DH, Vail DM. Mast cell tumors. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 4th ed. St. Louis: Saunders, 2007:402-424.
19. Seguin B, Besancon MF, McCallan JL, et al. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994-2002). J Vet Intern Med 2006;20:933-940.
20. Grier RL, Di Guardo G, Myers R, Merkley DF. Mast cell tumour destruction in dogs by hypotonic solution. J Small Anim Pract 1995;36:385-388.
21. Misdorp W. Incomplete surgery, local immunostimulation, and recurrence of some tumour types in dogs and cats. Vet Q 1987;9:279-286.
22. Zavodovskaya R, Chien MB, London CA. Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. J Vet Intern Med 2004;18:915-917.
23. Chaffin K, Thrall DE. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Vet Radiol Ultrasound 2002;43:392-395.
24. Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc 2001;218:1120-1123.
25. Weisse C, Shofer FS, Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. J Am Anim Hosp Assoc 2002;38:71-73.
26. Lara-Garcia A. CCNU (lomustine) induced hepatotoxicity in dogs. In: 24th annual meeting of Veterinary Cancer Society, New York, 2004.
27. Henry MC, Davis RD, Schein PS. Hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs: the use of serial percutaneous liver biopsies. Toxicol Appl Pharmacol 1973;25:410-417.
28. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:75-80.